Use Lay Language. CAA-ri : a Series of 28 Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03187886|
Recruitment Status : Terminated
First Posted : June 15, 2017
Last Update Posted : December 5, 2017
INTRODUCTION: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a very rare manifestation of cerebral amyloid angiopathy, characterized by acute/subacute neurological deterioration and T2/FLAIR corticosubcortical or deep white matter hyperintensity. With the advent of new diagnostic criteria, there are more and more case reports and series reported; nevertheless, MRI findings and follow-up data need to be thoroughly described.
OBJECTIVES: Our aim in this multicentrical and retrospective study was to describe the clinical and radiological features of patients with CAA-ri and assess long-term prognosis.
METHODS: We reviewed the characteristics of 28 patients with CAA-ri including clinical data, systematic MRI analysis, cerebrospinal fluid results (including Alzheimer's disease biomarkers) and APOE genotype.
HYPOTHESIS: We aimed at describing the clinical and radiological characteristics of a cohort of patients with CAA-ri.
|Condition or disease|
|Cerebral Amyloid Angiopathy Related Inflammation|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||28 participants|
|Official Title:||A Clinico-radiological Reappraisal of Cerebral Amyloid Angiopathy-related Inflammation in a Series of 28 Patients.|
|Actual Study Start Date :||January 1, 2017|
|Actual Primary Completion Date :||June 12, 2017|
|Actual Study Completion Date :||July 31, 2017|
- MRI results [ Time Frame: 1 day ]MRI results and Follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03187886
|Principal Investigator:||Xavier AYRIGNAC, MD||University Hospital, Montpellier|